These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20932925)

  • 21. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.
    Chen YB; Wang T; Hemmer MT; Brady C; Couriel DR; Alousi A; Pidala J; Urbano-Ispizua A; Choi SW; Nishihori T; Teshima T; Inamoto Y; Wirk B; Marks DI; Abdel-Azim H; Lehmann L; Yu L; Bitan M; Cairo MS; Qayed M; Salit R; Gale RP; Martino R; Jaglowski S; Bajel A; Savani B; Frangoul H; Lewis ID; Storek J; Askar M; Kharfan-Dabaja MA; Aljurf M; Ringden O; Reshef R; Olsson RF; Hashmi S; Seo S; Spitzer TR; MacMillan ML; Lazaryan A; Spellman SR; Arora M; Cutler CS
    Bone Marrow Transplant; 2017 Mar; 52(3):400-408. PubMed ID: 27941764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: Exposure-response analysis and population pharmacokinetics simulations.
    Teramoto M; Takahashi T; Matsumoto K; Jaber M; Kaida K; Tamaki H; Ikegame K; Yoshihara S
    Am J Hematol; 2024 Mar; 99(3):387-395. PubMed ID: 38165019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Rashid N; Gooley T; Furlong T; Lee SJ; Martin PJ; Storb R; Mielcarek M
    Transplant Cell Ther; 2023 Nov; 29(11):701.e1-701.e8. PubMed ID: 37657769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
    Cordón L; Chorão P; Martín-Herreros B; Montoro J; Balaguer A; Guerreiro M; Villalba M; Facal A; Asensi P; Solves P; Gómez I; Santiago M; Lamas B; Bataller A; Granados P; Sempere A; Sanz GF; Sanz MA; Sanz J
    Ann Hematol; 2024 Jul; 103(7):2475-2484. PubMed ID: 38634914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT].
    Sun W; Ma R; He Y; Bai L; Chen YY; Chen Y; Zhang YY; Wang JZ; Chen H; Zhang XH; Xu LP; Wang Y; Huang XJ; Sun YQ
    Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1444-1450. PubMed ID: 38044071
    [No Abstract]   [Full Text] [Related]  

  • 26. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.
    Li X; Brazauskas R; Wang Z; Al-Seraihy A; Baker KS; Cahn JY; Frangoul HA; Gajewski JL; Hale GA; Hsu JW; Kamble RT; Lazarus HM; Marks DI; Maziarz RT; Savani BN; Shah AJ; Shah N; Sorror ML; Wood WA; Majhail NS
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):587-92. PubMed ID: 24388803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil.
    Esquirol A; Pascual MJ; Montoro J; Piñana JL; Ferrà C; Herruzo B; Garcia-Cadenas I; Balaguer A; Perez A; Huguet M; Redondo S; Villalba M; Hernandez-Boluda JC; Chorao P; Hernani R; Sanz J; Solano C; Sierra J; Martino R
    Transplant Cell Ther; 2024 Aug; ():. PubMed ID: 39116938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A secondary CIBMTR analysis.
    Schoettler ML; Westbrook A; Watkins B; Stenger E; Qayed M; Chonat S; Williams KM
    Br J Haematol; 2024 Jul; 205(1):243-255. PubMed ID: 38817006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single-center experience.
    Poonsombudlert K; Mott S; Miller B; Yodsuwan R; Shaikh H; Strouse C; Lochner J; Farooq U; Magalhaes-Silverman M
    EJHaem; 2024 Jun; 5(3):578-583. PubMed ID: 38895065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use.
    Kovacsova F; Folber F; Weinbergerova B; Stepanova R; Kabut T; Tomiska M; Krejci M; Mayer J
    Ann Hematol; 2023 Dec; 102(12):3587-3591. PubMed ID: 37783854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study.
    Yeshurun M; Rozovski U; Pasvolsky O; Wolach O; Ram R; Amit O; Zuckerman T; Pek A; Rubinstein M; Sela-Navon M; Raanani P; Shargian-Alon L
    Blood Adv; 2020 Aug; 4(16):3822-3828. PubMed ID: 32790844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.
    Magenau J; Jaglowski S; Uberti J; Farag SS; Riwes MM; Pawarode A; Anand S; Ghosh M; Maciejewski J; Braun T; Devenport M; Lu S; Banerjee B; DaSilva C; Devine S; Zhang MJ; Burns LJ; Liu Y; Zheng P; Reddy P
    Blood; 2024 Jan; 143(1):21-31. PubMed ID: 37647633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.
    Li A; Wu Q; Davis C; Kirtane KS; Pham PD; Sorror ML; Lee SJ; Gopal AK; Dong JF; Garcia DA; Weiss NS; R Hingorani S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):570-576. PubMed ID: 30940363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of CYP3A5 gene polymorphism on tacrolimus concentration and adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation].
    Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):828-833. PubMed ID: 34788922
    [No Abstract]   [Full Text] [Related]  

  • 35. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
    Holtan SG; Verneris MR; Schultz KR; Newell LF; Meyers G; He F; DeFor TE; Vercellotti GM; Slungaard A; MacMillan ML; Cooley SA; Blazar BR; Panoskaltsis-Mortari A; Weisdorf DJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1029-36. PubMed ID: 25759146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation.
    El-Bietar J; Warren M; Dandoy C; Myers KC; Lane A; Wallace G; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1994-2001. PubMed ID: 26150023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel developments in the prophylaxis and treatment of acute GVHD.
    Jamy O; Zeiser R; Chen YB
    Blood; 2023 Sep; 142(12):1037-1046. PubMed ID: 37471585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.
    Dachy F; Furst S; Calmels B; Pagliardini T; Harbi S; Bouchacourt B; Calleja A; Lemarie C; Collignon A; Morel G; Legrand F; Bekrieva E; Granata A; Weiller PJ; Chabannon C; Schiano JM; Vey N; Blaise D; Devillier R
    Bone Marrow Transplant; 2023 Nov; 58(11):1179-1181. PubMed ID: 37558780
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
    Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients.
    Piemontese S; Lupo Stanghellini MT; Sora F; Sica S; Peccatori J; Marcatti M; Metafuni E; Giammarco S; Greco R; Bruno A; Ciceri F; Bacigalupo A; Chiusolo P
    Bone Marrow Transplant; 2024 May; 59(5):692-694. PubMed ID: 38355909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.